U.S. markets close in 1 hour 19 minutes
  • S&P 500

    3,857.30
    +1.94 (+0.05%)
     
  • Dow 30

    30,990.41
    +30.41 (+0.10%)
     
  • Nasdaq

    13,657.31
    +21.32 (+0.16%)
     
  • Russell 2000

    2,160.13
    -3.14 (-0.15%)
     
  • Crude Oil

    52.61
    -0.16 (-0.30%)
     
  • Gold

    1,848.80
    -6.40 (-0.34%)
     
  • Silver

    25.48
    -0.00 (-0.02%)
     
  • EUR/USD

    1.2170
    +0.0025 (+0.21%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • GBP/USD

    1.3735
    +0.0059 (+0.43%)
     
  • USD/JPY

    103.6480
    -0.1080 (-0.10%)
     
  • BTC-USD

    32,210.71
    +169.27 (+0.53%)
     
  • CMC Crypto 200

    650.90
    +3.57 (+0.55%)
     
  • FTSE 100

    6,654.01
    +15.16 (+0.23%)
     
  • Nikkei 225

    28,546.18
    -276.11 (-0.96%)
     

Brazil institute says CoronaVac efficacy above 50%, delays full results

RIO DE JANEIRO, Dec 23 (Reuters) - The COVID-19 vaccine developed by China's Sinovac Biotech meets the 50% threshold for efficacy set by Brazilian health regulator Anvisa, the biomedical center running late-stage trials in Brazil said on Wednesday.

The Sao Paulo state government's Butantan Institute said that Sinovac had asked to delay releasing precise efficacy data for the vaccine, called CoronaVac, for up to 15 days while the company consolidates data from global trials. (Reporting by Gabriel Stargardter and Pedro Fonseca Editing by Brad Haynes)